Compare Bandwidth Inc (BAND) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs BridgeBio Pharma Inc — how do they compare? Bandwidth Inc trades at $51.51 (market cap $1.70B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 9.8× Bandwidth Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Bandwidth Inc nearer its low. Which is the better fit depends on your goals.
| BAND | BBIO | |
|---|---|---|
Market Cap | $1.70B | $16.61B |
Sector | Technology | Health |
52-Week High | $78.44 | $90.17 |
52-Week Low | $12.82 | $47.29 |
Enterprise Value | $2.08B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $49.96, up 11.79% in 24 hours, with bullish technical signals and strong analyst support. Recent Q2 2026 earnings beat estimates, driven by AI-driven communications demand, with revenue up 22% year-over-year. The company raised its 2026 outlook, reflecting operational momentum and margin expansion.
Outlook is positive with a $75.25 consensus price target, though risks include thin net margins and high valuation multiples. Growth hinges on AI adoption and enterprise wins, but competitive pressures and execution challenges remain key watchpoints for investors.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
